ITRAQ-Based Proteomic Analysis of Ginsenoside F₂ on Human Gastric Carcinoma Cells SGC7901.

ABSTRACT: Ginsenoside F₂ (F₂), a protopanaxdiol type of saponin, was reported to inhibit human gastric cancer cells SGC7901. To better understand the molecular mechanisms of F₂, an iTRAQ-based proteomics approach was applied to define protein expression profiles in SGC7901 cells in response to lower dose (20 μM) and shorter duration (12 hour) of F₂ treatment, compared with previous study. 205 proteins were screened in terms of the change in their expression level which met our predefined criteria. Further bioinformatics and experiments demonstrated that F₂ treatment downregulated PRR5 and RPS15 and upregulated RPL26, which are implicated in ribosomal protein-p53 signaling pathway. F₂ also inhibited CISD2, Bcl-xl, and NLRX1, whi

SUBMITTER: Mao Q 

PROVIDER: S-EPMC5088344 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature